Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Moderna Analyst: Phase 3 Coronavirus Data Could Arrive As Soon As October
Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B+ In Orders Over Next Few Years
Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill
Michael Yee Recent News
Jefferies On Gilead: 'We See Better Days Ahead'
3 Highlights From A Spark Therapeutics Fireside Chat
RBC Hints At Potential M&A For Kite Pharma
There's A Historical Precedent For The Biotech Selloff
M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down
Is More M&A On The Way For Large-Cap Biotechs?
RBC's Michael Yee Still Sees Value in Biogen's Long-Term Pipeline
Biogen's Parkinson's Antibody Could Boost Prothena, RBC Says
Large-Cap Biotechs Poised For Second-Half Rally, RBC Says
Top Street Analysts Like Gilead Sciences
Can Gilead Really Post EPS Growth Above 50%?
What's Wall Street Been Saying About Gilead Lately?
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Will Intercept Pharma Outperform? These Analysts Think So
XenoPort Soars 9% Following Comments From RBC's Michael Yee
Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More
RBC Sees Weak Merck Data As Positive For Gilead
Why Investors Should Closely Watch Celgene
Tekmira Sinks 15%; Anti-Ebola Drug Trial Halted For Safety Concerns